DDInter1589 DDInter1676
A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Rifabutin {u} (Compound) resembles {v} (Compound) Rifampicin
Rifabutin {u} (Compound) resembles {v} (Compound) Rifapentine
Rifabutin {u} (Compound) binds {v} (Gene) CYP3A4
Rifabutin {u} (Compound) upregulates {v} (Gene) MAL
Rifabutin {u} (Compound) is included by {v} (Pharmacologic Class) Rifamycins
Rifabutin {u} (Compound) downregulates {v} (Gene) CDC20
Rifabutin {u} (Compound) causes {v} (Side Effect) Neutropenia
Rifabutin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Rifabutin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Miconazole
Rifabutin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Rifabutin (Compound) resembles Rifampicin (Compound)
Rifabutin (Compound) resembles Rifapentine (Compound)
Rifabutin (Compound) binds CYP3A4 (Gene)
Rifabutin (Compound) upregulates MAL (Gene)
Rifabutin (Compound) is included by Rifamycins (Pharmacologic Class)
Rifabutin (Compound) downregulates CDC20 (Gene)
Rifabutin (Compound) causes Neutropenia (Side Effect)
Rifabutin may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Rifabutin may cause a minor interaction that can limit clinical effects when taken with Miconazole
Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib